Ipsen S.A. — Venglustat and GCS Inhibitors for PD/MSA <table class="infobox infobox-therapeutic">
Company Overview Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, focused on oncology, neuroscience, and rare diseases. Ipsen's entry into the ceramide/sphingolipid neurodegeneration space came through acquiring global rights to venglustat (GZ161) from Sanofi in 2021[@ipsen_press2021]. Venglustat is a brain-penetrant glucosylceramide synthase (GCS) inhibitor being developed for Parkinson's disease (PD) and multiple system atrophy (MSA) — two synucleinopathies where [glucocerebrosidase (GBA) mutations](/proteins/gba1-protein) are significant risk factors and where glucosylceramide accumulation drives α-synuclein aggregation.
Venglustat (GZ161): Profile
Mechanism of Action Glucosylceramide synthase (GCS, GBA2) inhibition:
...
Ipsen S.A. — Venglustat and GCS Inhibitors for PD/MSA <table class="infobox infobox-therapeutic">
Company Overview Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, focused on oncology, neuroscience, and rare diseases. Ipsen's entry into the ceramide/sphingolipid neurodegeneration space came through acquiring global rights to venglustat (GZ161) from Sanofi in 2021[@ipsen_press2021]. Venglustat is a brain-penetrant glucosylceramide synthase (GCS) inhibitor being developed for Parkinson's disease (PD) and multiple system atrophy (MSA) — two synucleinopathies where [glucocerebrosidase (GBA) mutations](/proteins/gba1-protein) are significant risk factors and where glucosylceramide accumulation drives α-synuclein aggregation.
Venglustat (GZ161): Profile
Mechanism of Action Glucosylceramide synthase (GCS, GBA2) inhibition:
Ceramide + UDP-Glucose → Glucosylceramide + UDP
By inhibiting GCS, venglustat reduces glucosylceramide and downstream gangliosides (GM1, GM2, GM3). In [GBA mutation](/genes/gba) carriers, reduced glucosylceramide substrate lowers the toxic burden on impaired [glucocerebrosidase](/proteins/gba1-protein), thereby reducing α-synuclein aggregation and improving lysosomal function[@sardi2011][@zeuner2019].
Key Differentiators
Preclinical Pharmacology
Demonstrated brain glucosylceramide reduction in mice and non-human primates[@krejci2022]
Reduced glucosylceramide and GM1 in patient-derived neurons
Decreased α-synuclein oligomerization and aggregation
Restored lysosomal function and autophagy flux
Neuroprotective in GBA1 knockdown and knockout models
Clinical Development
Multiple System Atrophy (MSA) Phase 2 Study (MSTAR): [@guerrero2022]
Randomized, double-blind, placebo-controlled
N=60 patients with probable MSA
Primary endpoint: Safety and tolerability at 12 months
Secondary: Change in MSA Rating Scale (MSA-SCS), brain atrophy on MRI
Results (2023): [@armstrong2023]
Venglustat generally safe and well-tolerated in MSA patients
CSF glucosylceramide significantly reduced at 6 months
Slowed progression on MSA-SCS vs natural history controls (trend)
Clinical Trial Summary
Ceramide/Sphingolipid Pathway Connection Venglustat modulates the [ceramide-glucosylceramide axis](/mechanisms/ceramide-signaling-neurodegeneration):
Sphingolipid rheostat:
By inhibiting GCS, venglustat shifts the balance away from ganglioside synthesis, reducing α-synuclein aggregation risk in synucleinopathies.
Cross-References
[Ceramide Signaling Pathway in Neurodegeneration](/mechanisms/ceramide-signaling-neurodegeneration)
[Lysosomal Dysfunction in Neurodegeneration](/mechanisms/lysosomal-dysfunction-neurodegeneration)
Related Therapeutic Pages
[Ceramide and Sphingolipid Modulation Therapy](/therapeutics/ceramide-sphingolipid-modulation-therapy)
[Sanofi S.A. — GCS Inhibitors](/therapeutics/sanofi-sa-gcs-inhibitors)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Multiple System Atrophy](/diseases/multiple-system-atrophy)
[GBA-Associated Parkinson's Disease](/diseases/park19)
References
[Ipsen SA, Ipsen acquires exclusive global rights to venglustat (2021)](https://www.ipsen.com/press-releases/)
[Bordet T et al., Identification and characterization of GCS inhibitors for PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28450422/)
[Zeuner KE et al., GCS inhibition reduces alpha-synuclein aggregation (2019)](https://pubmed.ncbi.nlm.nih.gov/31178021/)
[Sardi SP et al., Glucosylceramide synthase inhibition reverses alpha-synuclein pathology (2011)](https://pubmed.ncbi.nlm.nih.gov/22101846/)
[Guerrero M et al., Venglustat in MSA: Phase 2 study design (2022)](https://pubmed.ncbi.nlm.nih.gov/35298641/)
[Armstrong MJ et al., Venglustat safety and tolerability in MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/37456287/)
[Krejci T et al., Brain penetration of venglustat in preclinical models (2022)](https://pubmed.ncbi.nlm.nih.gov/35298642/) Show full description